European Medicines Agency issues positive recommendation on generic zoledronic acid

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Zoledronic Acid Accord 4mg/5ml concentrate for solution for infusion intended for the prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone, and the treatment of tumour-induced hypercalcaemia (TIH). Read more here.